Moderna Stock Pops 14% on Early Hantavirus Vaccine Work

Moderna’s shares jumped about 14% after news of early hantavirus vaccine research with the U.S. Army and Korea University, though executives say the work is in its infancy and not close to a vaccine. Experts note funding has been limited because hantavirus outbreaks are rare, suggesting a vaccine could be years or even a decade away. Wall Street shows a Hold consensus on MRNA with a $41.75 target implying potential downside, so the stock move reflects long‑term research interest rather than near‑term product prospects.